Enzalutamide 40 MG

DRUG3 trials

Sponsors

Institute of Cancer Research, United Kingdom, Grupo Español de Tumores Huérfanos e Infrecuentes, Zhongnan Hospital

Conditions

Castrate Resistant Prostate CancerMetastatic Castration Resistant Prostate CancerOvarian CancerProstate Cancer

Phase 1

Combination Study of AZD5069 and Enzalutamide.

TerminatedNCT03177187

Institute of Cancer Research, United KingdomMetastatic Castration Resistant Prostate Cancer

Start: 2017-11-13End: 2022-11-16Updated: 2024-09-26

Phase 2

Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study

CompletedNCT03464201

Grupo Español de Tumores Huérfanos e InfrecuentesOvarian Cancer

Start: 2018-04-13End: 2020-11-11Updated: 2023-02-22

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

Zhongnan HospitalCastrate Resistant Prostate Cancer, Prostate Cancer

Start: 2024-06-01End: 2025-12-31Target: 120Updated: 2024-02-28

Related Papers

Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).

2024-10-241 citations

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.

2024-02-0738 citations

Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)

BMJ Open2021-09-013 citations